The efficiency of treatment of human infections with the unicellular eukaryotic pathogens
such as fungi and protozoa remains deeply unsatisfactory. For example, the mortality rates …

There are a number of biologic oxidations in Trypanosoma cruzi that generate O2-and/or
H2O2. In addition, intracellular reduction followed by autoxidation yielding O2-and H2O2 …

As a continuation of our project aimed at the search for new and safe chemotherapeutic and
chemoprophylactic agents against American trypanosomiasis (Chagas' disease), several …

Chagas disease affects 7.7 million people and 28 million people are at risk of acquiring the
disease in 15 endemic countries of Latin America. Benznidazole and nifurtimox are drugs …

Trypanosoma cruzi causes Chagas disease (American trypanosomiasis), which threatens
the lives of millions of people and remains incurable in its chronic stage. The antifungal drug …

The protozoan parasite, Trypanosoma cruzi, causes the most prevalent parasitic infection in
the American continent. It gives rise to life-long infection in humans and results in severe …

Pathogenic protozoa threaten lives of several hundred million people throughout the world
and are responsible for large numbers of deaths globally. The parasites are transmitted to …

Summary Sterol 14α-demethylases (CYP51) serve as primary targets for antifungal drugs,
and specific inhibition of CYP51s in protozoan parasites Trypanosoma brucei (TB) and …

There are at least two obvious features that must be considered upon targeting specific
metabolic pathways/enzymes for drug development: the pathway must be essential and the …

We report the ultrastructural alterations induced during the proliferative stages of
Trypanosoma (Schizotrypanum) cruzi, the causative agent of Chagas' disease, by two …